Xenon Pharmaceuticals (XENE) Consolidated Net Income (2013 - 2026)
Xenon Pharmaceuticals (XENE) reported Consolidated Net Income of -$102.3 million for Q1 2026, down 57.27% year-over-year from -$239.4 million in Q1 2025, and down 142.17% on a QoQ basis from $242.6 million in Q4 2025.
Xenon Pharmaceuticals (XENE) has 14 years of Consolidated Net Income data on file, last reported at -$102.3 million in Q1 2026.
- Quarterly Consolidated Net Income fell 57.27% year-over-year to -$102.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$35.3 million (up 86.24% YoY) and the FY2025 annual result came in at $2.0 million, up 100.82% from the prior year.
- Consolidated Net Income declined to -$102.3 million in Q1 2026 per XENE's latest filing, from $242.6 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at $242.6 million in Q4 2025 and bottomed at -$102.3 million in Q1 2026.
- The 5-year median for Consolidated Net Income is -$47.9 million (2024), against an average of -$37.4 million.
- The widest annual swing landed in 2022, when Consolidated Net Income plunged 140.53%; it then surged 443.27% in 2025.
- Tracing XENE's Consolidated Net Income over 5 years: stood at -$33.5 million in 2022, then slipped by 9.18% to -$36.5 million in 2023, then tumbled by 93.37% to -$70.7 million in 2024, then surged by 443.27% to $242.6 million in 2025, then plunged by 142.17% to -$102.3 million in 2026.
- Per Business Quant, the three latest XENE Consolidated Net Income figures stand at -$102.3 million (Q1 2026), $242.6 million (Q4 2025), and -$90.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Xenon Pharmaceuticals | 4.78 Bn | 4.78 Bn | - | -102.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -102.30 Mn |
| Dec 31, 2025 | 242.61 Mn |
| Sep 30, 2025 | -90.90 Mn |
| Jun 30, 2025 | -84.71 Mn |
| Mar 31, 2025 | -65.05 Mn |
| Dec 31, 2024 | -70.68 Mn |
| Sep 30, 2024 | -62.79 Mn |
| Jun 30, 2024 | -57.92 Mn |
| Mar 31, 2024 | -47.93 Mn |
| Dec 31, 2023 | -36.55 Mn |
| Sep 30, 2023 | -48.46 Mn |
| Jun 30, 2023 | -47.46 Mn |
| Mar 31, 2023 | -41.73 Mn |
| Dec 31, 2022 | -33.48 Mn |
| Sep 30, 2022 | -37.15 Mn |
| Jun 30, 2022 | -31.16 Mn |
| Mar 31, 2022 | -19.67 Mn |
| Dec 31, 2021 | -25.56 Mn |
| Sep 30, 2021 | -15.45 Mn |
| Jun 30, 2021 | -22.11 Mn |
| Mar 31, 2021 | -15.76 Mn |
| Dec 31, 2020 | -12.32 Mn |
| Sep 30, 2020 | -8.86 Mn |
| Jun 30, 2020 | -175,000.00 |
| Mar 31, 2020 | -7.48 Mn |
| Dec 31, 2019 | -11.38 Mn |
| Sep 30, 2019 | -8.87 Mn |
| Jun 30, 2019 | -10.01 Mn |
| Mar 31, 2019 | -11.34 Mn |
| Dec 31, 2018 | -8.56 Mn |
| Sep 30, 2018 | -14.38 Mn |
| Jun 30, 2018 | -7.80 Mn |
| Mar 31, 2018 | -3.76 Mn |
| Dec 31, 2017 | -7.96 Mn |
| Sep 30, 2017 | -8.52 Mn |
| Jun 30, 2017 | -7.78 Mn |
| Mar 31, 2017 | -7.84 Mn |
| Dec 31, 2016 | -5.29 Mn |
| Sep 30, 2016 | -7.22 Mn |
| Jun 30, 2016 | -6.24 Mn |
| Mar 31, 2016 | -5.56 Mn |
| Dec 31, 2015 | -2.51 Mn |
| Sep 30, 2015 | -690,000.00 |
| Jun 30, 2015 | 362,000.00 |
| Mar 31, 2015 | -5.99 Mn |
| Dec 31, 2014 | 187,000.00 |
| Sep 30, 2014 | 8.80 Mn |
| Jun 30, 2014 | 1.52 Mn |
| Mar 31, 2014 | 1.17 Mn |
| Dec 31, 2013 | 2.16 Mn |
| Sep 30, 2013 | 6.62 Mn |